Pilot Study to Evaluate 18F-fluorodeoxyglucose (FDG) Positron Emission Tomography /Computed Tomography (PET/CT) in Prediction of Early Response to Chemotherapy in Ovarian Cancer.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Memorial Sloan Kettering Cancer Center
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Histologically proven ovarian cancer at diagnosis of any stage.
Patients with evidence of disease that is radiographically measurable (CT scan)
Patients have planned to undergo standard chemotherapy. Dose and schedule will be determined per treating physician
You may not be if
Patients with any other malignancy active within 5 years except for non-melanoma skin cancer, or carcinoma in situ of the cervix.
Patients with an active infection
Patients of childbearing potential are excluded from this study.
Patients who have expected survival \< 3 months.
Patients not planning or able to receive the outlined chemotherapy regimen as part of standard practice.
Patient unable to complete study
Clareo Health | Pilot Study to Evaluate 18F-fluorodeoxyglucose (FDG) Positron Emission Tomography /Computed Tomography (PET/CT) in Prediction of Early Response to Chemotherapy in Ovarian Cancer.
